Starting mid-2025, Cigna’s Evernorth will offer copay caps on GLP-1 weight loss drugs to businesses that currently do not cover these costly medications. Harold Carter, Evernorth’s senior vice president, said the agreement ensures consistent pricing for pharmacies and Evernorth’s home delivery service, while simplifying pre-authorization. Currently, only half of Cigna Group’s clients cover these drugs. For those who do, savings could reach up to 20%.
The move follows Lilly’s Zepbound being overshadowed after CVS Caremark named Wegovy its preferred weight-loss drug. Analysts report net discounts for employers range from 30% to 50%. Zepbound lists at \$1,100 per month with a net price of \$725, while Wegovy lists at \$1,350 but averaged \$616 net in March. Compared to out-of-pocket costs, the new copay caps offer over 50% savings.
Evernorth’s plan comes ahead of Medicare drug pricing cuts scheduled for 2027 under the Inflation Reduction Act, which will benefit Novo Nordisk’s products. Eli Lilly remains committed to expanding partnerships to improve access to Zepbound.
While Cigna shows growth potential, some analysts believe AI stocks offer higher returns and lower risks. For those interested in promising AI investments, a report highlights a top affordable AI stock with 100x upside potential.
Related Topics:
Semaglutide Boosts Heart Health Before Weight Loss Starts
Viva Leisure Invests In Gold Coast Sports Drink Startup Gorilla X
